Jane Smith

Jane Smith

President at BioCrossroads

Health Technology
Consumer Services
Finance

Profile

Jane Dunigan-Smith joined BioCrossroads as the Senior Vice President and Chief Strategy Officer in May 2022.
She also serves as the Managing Director of BioCrossroads Seed Funds.
Prior to joining BioCrossroads, she was the Chief of Staff for Global Commercial Services and the Customer Experience Hub at Eli Lilly and Company, leading the customer engagement transformation efforts and development of key strategies for the company’s commercial capabilities.
In her nearly 19 years at Lilly, she held a variety of roles in corporate strategy, operations, and numerous global and U.S.
marketing teams.
She also pioneered and led launch readiness efforts across the diabetes business unit, ensuring the successful global launches of several key diabetes portfolio products.
She is a member of the board of directors of Allinaire Therapeutics.
Early in her career, she was a CPA and audit manager at PricewaterhouseCoopers in Chicago.
Jane holds a bachelor’s degree in accounting and finance as well as an MBA from the Kelley School of Business at Indiana University.

Jane Smith active positions

CompaniesPositionStart
President 2022-04-30
Director/Board Member 2022-08-31
Director/Board Member 2022-08-31
All active positions of Jane Smith

Former positions of Jane Smith

CompaniesPositionEnd
ELI LILLY AND COMPANY Private Equity Investor 2019-06-29
See the detail of Jane Smith's experience

Training of Jane Smith

Indiana University Masters Business Admin
Kelley School of Business Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jane Smith's experience

Connections

100 +

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
ELI LILLY AND COMPANY

Health Technology

Private companies3

Finance

Technology Services

Health Technology

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW